company background image
BIOC

Biocept NasdaqCM:BIOC Stock Report

Last Price

US$1.17

Market Cap

US$19.8m

7D

11.4%

1Y

-70.8%

Updated

12 Aug, 2022

Data

Company Financials +
BIOC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BIOC Stock Overview

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample.

Biocept Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biocept
Historical stock prices
Current Share PriceUS$1.17
52 Week HighUS$4.44
52 Week LowUS$0.84
Beta0.82
1 Month Change19.38%
3 Month Change-24.03%
1 Year Change-70.75%
3 Year Change-87.25%
5 Year Change-99.68%
Change since IPO-99.99%

Recent News & Updates

Shareholder Returns

BIOCUS BiotechsUS Market
7D11.4%1.2%1.3%
1Y-70.8%-23.0%-11.7%

Return vs Industry: BIOC underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: BIOC underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is BIOC's price volatile compared to industry and market?
BIOC volatility
BIOC Average Weekly Movement9.4%
Biotechs Industry Average Movement12.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: BIOC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: BIOC's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997179Sam Riccitellihttps://biocept.com

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer.

Biocept Fundamentals Summary

How do Biocept's earnings and revenue compare to its market cap?
BIOC fundamental statistics
Market CapUS$19.80m
Earnings (TTM)-US$8.19m
Revenue (TTM)US$63.44m

0.3x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIOC income statement (TTM)
RevenueUS$63.44m
Cost of RevenueUS$39.09m
Gross ProfitUS$24.35m
Other ExpensesUS$32.54m
Earnings-US$8.19m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.48
Gross Margin38.38%
Net Profit Margin-12.91%
Debt/Equity Ratio0%

How did BIOC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BIOC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIOC?

Other financial metrics that can be useful for relative valuation.

BIOC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.07x
Enterprise Value/EBITDA-0.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BIOC's PS Ratio compare to its peers?

BIOC PS Ratio vs Peers
The above table shows the PS ratio for BIOC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average32.9x
LOGC LogicBio Therapeutics
2.6x-93.5%US$22.2m
SBFM Sunshine Biopharma
57.4xn/aUS$23.4m
XBIO Xenetic Biosciences
8.9x10.4%US$13.2m
THER Theralink Technologies
62.9xn/aUS$26.9m
BIOC Biocept
0.3x7.4%US$20.3m

Price-To-Sales vs Peers: BIOC is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (31.7x).


Price to Earnings Ratio vs Industry

How does BIOC's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: BIOC is good value based on its Price-To-Sales Ratio (0.3x) compared to the US Biotechs industry average (16.5x)


Price to Sales Ratio vs Fair Ratio

What is BIOC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIOC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: BIOC is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).


Share Price vs Fair Value

What is the Fair Price of BIOC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIOC ($1.17) is trading above our estimate of fair value ($0.64)

Significantly Below Fair Value: BIOC is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is Biocept forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


32.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BIOC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BIOC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BIOC's revenue (7.4% per year) is forecast to grow slower than the US market (7.9% per year).

High Growth Revenue: BIOC's revenue (7.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BIOC's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Biocept performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


18.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BIOC is currently unprofitable.

Growing Profit Margin: BIOC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BIOC is unprofitable, but has reduced losses over the past 5 years at a rate of 18.6% per year.

Accelerating Growth: Unable to compare BIOC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIOC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: BIOC has a negative Return on Equity (-22.12%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Biocept's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BIOC's short term assets ($47.6M) exceed its short term liabilities ($14.1M).

Long Term Liabilities: BIOC's short term assets ($47.6M) exceed its long term liabilities ($10.8M).


Debt to Equity History and Analysis

Debt Level: BIOC is debt free.

Reducing Debt: BIOC has no debt compared to 5 years ago when its debt to equity ratio was 25.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BIOC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BIOC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 10.1% per year.


Discover healthy companies

Dividend

What is Biocept current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIOC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIOC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIOC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BIOC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Sam Riccitelli (63 yo)

0.50

Tenure

US$103,041

Compensation

Mr. Samuel D. Riccitelli, also known as Sam, serves as Independent Director at Biocept, Inc. since October 21, 2020 and Independent Chairman since July 2021. Mr. Riccitelli serves as Interim President and...


Leadership Team

Experienced Management: BIOC's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: BIOC's board of directors are seasoned and experienced ( 11.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.3%.


Top Shareholders

Company Information

Biocept, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Biocept, Inc.
  • Ticker: BIOC
  • Exchange: NasdaqCM
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$19.800m
  • Shares outstanding: 16.92m
  • Website: https://biocept.com

Number of Employees


Location

  • Biocept, Inc.
  • 9955 Mesa Rim Road
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.